Steven Cohen’s Outlook Therapeutics OTLK Stock Holding History

Steven Cohen’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,038	Closed	-$5.98K	–	4443
2026 Q1	$5.98K	Buy	+29,038	New	+$12.5K	﹤0.01%	3701

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Steven Cohen's OTLK Position: Q2 2026 in Review

Steven Cohen sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 29,038 shares — an estimated $5.98K sold.

Steven Cohen first reported a position in OTLK in Q1 2026 and held it in 1 quarter. The position peaked at $5.98K in Q1 2026. 70 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Steven Cohen reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 29,038 Outlook Therapeutics shares in Q2 2026, an estimated $5.98K.
Steven Cohen first reported a position in Outlook Therapeutics in Q1 2026 and held it in 1 quarter.
Steven Cohen's Outlook Therapeutics position peaked at $5.98K in Q1 2026.
70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.